Postivie Early Phase 1 Results For AG-120 In IDH1 Mutated AML
Tuesday, November 25, 2014 - 11:40
in Health & Medicine
Results presented at the European Organisation for Research and Treatment of Cancer Symposium in Barcelona show "extremely promising" early phase 1 clinical trial results for the investigational drug AG-120 against the subset of patients with acute myeloid leukemia (AML) harboring mutations in the gene IDH1. The finding builds on phase 1 results of a related drug, AG-221, against IDH2 mutations, presented at the most recent meeting of the American Association for Cancer Research. Results at this stage are preliminary, based on 17 patients. The IDH1 mutation is found in 15-20 percent of all cases of AML, totaling about 3,500 cases of IDH1 AML per year. read more